Perspectives · Consolidation

The Legal Moat

Where you can build a healthcare platform in Europe — and where the law, or the buyers, got there first

Corryk · July 2026

Every buy-and-build thesis starts with a fragmentation slide: thousands of small, owner-run clinics, a demographic tailwind, and the promise that a disciplined consolidator can turn a cottage industry into a platform. The slide is usually true, and on its own close to useless — because fragmentation tells you where the opportunity looks like it is, not where it can be captured.

Three things have to line up before a fragmented market becomes a platform. It has to be fragmented enough that there is something to roll up — the whitespace. Corporate or chain ownership has to be legally permitted — the walls. And it has to be early enough that the assets are not already inside someone else’s platform — the question of saturation. When all three align, you have a roll-up. When any one fails, you have a trap, a non-market, or a latecomer’s auction. The evidence that follows shows how rarely they align.

The most fragmented corner of European healthcare is also one of the least investable. Fragmentation is an invitation; the law decides whether you can accept it.

— Corryk

In brief

One — fragmentation is necessary but nowhere near sufficient. The roll-up prize is the intersection of whitespace, legal permission and low saturation, and the three seldom coincide. A market can be gloriously fragmented and completely un-investable at once.

Two — ownership law, not demand, draws the perimeter. Community pharmacy is the cleanest case: corporate ownership is banned in Germany, France, Spain, Austria and Finland and capped in Denmark, yet open in the UK, Netherlands, Belgium, Sweden, Norway, Ireland, Switzerland — and, since a 2017 reform, Italy. Europe’s four largest pharmacy networks are Spain, France, Italy and Germany; three of the four are legally shut (Exhibit 1).

Three — where roll-ups are legal, most of the deal flow is invisible. A large share of consolidation happens at the asset level — a clinic or home changes operator without a share sale or a beneficial-owner filing. In the UK, where the regulator publishes the record, these re-registrations run at roughly 750 a year and split almost evenly between dental (~35%) and elderly care (~34%) — and are visible, by name, before any announced process (Exhibits 6–8).

The roll-up you can execute is the narrow set of subsegments that are fragmented, legally open, and not yet consolidated — and the fastest way to find live deals is to watch the regulator, not the deal wires.

A note on the data

The ownership-law perimeter is drawn from the governing statutes and regulators, named market by market. Pharmacy counts and densities are on a single comparable basis (ABDA / PGEU). Consolidation is described through public transactions and named platforms, not estimates. The asset-deal analysis is a transparent reading of the UK Care Quality Commission’s published care directory; where a category is attached to a site it is inferred from the site’s registered name, not asserted. Two disciplines throughout: ownership regimes change — the matrix is a snapshot to verify at deal time — and we describe the legal perimeter, not legal advice.

The three axes

1 · Whitespace, and the wall around it

Healthcare delivery is a cottage industry almost everywhere: the typical provider is a single site run by the clinician who owns it. The tail of independents is longest closest to the high street — pharmacy, dentistry, optometry, physiotherapy, primary care — and community pharmacy is the extreme. It is also where whitespace and wall collide most sharply, because the markets with the most pharmacies to buy are disproportionately the ones where you may not buy them.

Closed corporate ownership prohibited (owner must be a licensed pharmacist)   Open chains permitted — Italy opened in 2017   Capped permitted but limited outlets per owner.

Spain has the densest pharmacy network in the core of Europe — and it is legally sealed. France and Germany, second and fourth by count, are sealed too; only Italy among the four giants is open, and only since 2017. The fragmentation is real to the last decimal: in Germany, 12,530 pharmacy owners hold 17,041 premises — barely more than one each, because the law forbids more. That is one of the largest obvious pharmacy roll-ups in European care that cannot be built under current ownership law — and Spain, with 22,222 pharmacies under the same one-licence-per-pharmacist logic, is larger still.

2 · The whitespace is shrinking on its own

Whitespace is not static. Across most of Europe the number of pharmacies per head has been falling for two decades — closures and pharmacist-to-pharmacist mergers thinning the independent base whether or not capital is allowed in.

Germany has lost roughly a quarter of its pharmacy density since 2004 (26 to 20 per 100,000); Belgium and France have drifted down a similar path. The read for an acquirer is two-sided. In open markets, a shrinking base of independents means the window to source from owner-operators is closing — the sellers are ageing out and their sites are consolidating regardless. In closed markets, the assets are disappearing rather than being rolled up: the whitespace erodes without ever becoming investable. Either way, the pool is finite and getting smaller, which raises the premium on being early.

3 · Walls — the ownership-law perimeter

Whether a corporate or financial buyer may own a healthcare business is a statutory question, and the answer varies by subsegment and country — from full corporate freedom, through capped or clinician-majority structures, to outright prohibition. It is one of the most decisive facts in European healthcare M&A, and the one most routinely underweighted next to demand and fragmentation.

Exhibit 3 · The ownership-law perimeter, by market

Whether corporate / chain ownership is legally available. Open = permitted; Gated = permitted but capped or clinician-majority; Closed = corporate ownership prohibited (owner must be a licensed professional).

Sources: national pharmacy and healthcare-ownership statutes and regulators (Fremdbesitzverbot / ApoG DE; Code de la santé publique FR; Ley 16/1997 ES; Law 124/2017 IT; Apotekloven NO; Pharmacy Act 2007 IE; Apothekengesetz AT; GPhC / Dentists Act 2006 UK). Snapshot; verify at deal time.

Read the pharmacy column and Europe divides in two. In Germany, France, Spain, Finland and Austria you cannot own a pharmacy unless you are a pharmacist; corporate consolidation is not difficult, it is illegal. In the UK, Netherlands, Belgium, Sweden, Norway, Ireland and Switzerland, and now Italy, you can. Dentistry shows the opposite pattern — open almost everywhere, gated only where regulators pushed back on investor models (Germany’s MVZ debate, France after Dentexia, Denmark’s dentist-majority rule). That is why dental, not pharmacy, has been the most-worked roll-up in European care despite pharmacy’s larger whitespace: the wall is lower.

Saturation

4 · Where the buyers already are

The third axis is time. A fragmented, legally open subsegment is only an opportunity if consolidation has not already run its course — and in several open markets it has. Where deregulation came early, the whitespace is gone: in Norway, three chains took roughly 85% of pharmacies within two decades of the 2001 liberalisation. In the pan-European subsegments — veterinary, laboratories, elderly care — a handful of sponsor-backed platforms now span the Continent.

Exhibit 4 · The consolidators are already pan-European

Illustrative named platforms with public footprints, by subsegment. Cited as market structure, not as transactions.

Sources: company disclosures, regulator registers and public transaction press. Illustrative of market structure; not an ownership assertion for any individual site.

5 · Italy’s natural experiment

Pharmacy has the deepest whitespace of any subsegment and, across Germany, France, Spain, Austria and Finland, the highest wall: the whitespace is maximal precisely where a corporate buyer is locked out. Italy is the experiment that proves the point. Until 2017 it sat in the closed camp with its neighbours. The 2017 competition law legalised corporate ownership, subject to a 20% regional cap. Nothing about Italian demographics or fragmentation changed — only the wall — and chains appeared where a year earlier there had been none.

Two readings follow. First, the opening is real: domestic and international platforms (Dr Max, Lloyds and others) entered a market that had been legally sealed the year before. Second, it is young — national penetration is around 5%, and even the most-consolidated region, Lombardy, sits at 12%, well under the 20% ceiling. Contrast Norway’s ~85%: same legal openness, twenty years apart on the saturation clock. In the closed markets the binding constraint is a statute, and the entire opportunity is contingent on whether — and when — it moves.

The rule the pharmacy case makes vivid: rank the closed-but-fragmented subsegments not by how attractive they look, but by how likely the wall is to fall. A legally sealed market is worth nothing to a buyer until it opens — and then a great deal, quickly, as Italy showed.

The invisible deal market

6 · The deals the wires never see

Where roll-ups are legal and live, most of the deal flow never appears where dealmakers look. A large share of consolidation happens at the asset level — a single clinic, practice or home transferred to a new operator — without a share sale, a change in ultimate beneficial ownership, or any filing a corporate database records. To the standard deal toolkit, these transactions are invisible. They are not invisible to the health regulator: when an operator changes, the site is de-registered under the old provider and re-registered under the new one at the same address. Matching the two recovers the ownership change directly from the public record.

Applied to the UK, the method surfaces roughly 11,450 cross-operator changes over fifteen years. The category mix corrects a common assumption: this is not a dental story alone. Dental (~35%) and elderly care (~34%) are the two dominant categories in almost equal measure, with GP practices (~9%) behind. Dental is fragmented, legally open, and consolidates through single-practice transfers; elderly care churns operators constantly as homes change hands and struggling providers exit. The category split is itself an origination signal — it shows where operational control is actually changing, which is not the same as where announced M&A happens.

7 · A persistent, decade-long flow

The flow is persistent — roughly seven to nine hundred changes every year for fifteen years, through cycles. Behind it, about 7,660 distinct sellers handed sites to about 5,540 distinct buyers: net consolidation, thousands of independents moving into fewer hands, one asset at a time. This is a live origination feed — a register of who is changing hands ahead of any announced process — and a competitive-intelligence feed. Neither is available from conventional deal data, because conventional deal data watches the wrong layer.

8 · The consolidators, by name

Because the record names the acquiring provider, the same data reveals who is rolling up, and in what.

The most active buyers are exactly the platforms one would expect from the two dominant categories: dental chains (Time for Teeth, Envisage, Portman, Dentex, Rodericks) and care groups (Voyage, Achieve Together, Anchor Hanover, HC-One, Care UK), each absorbing dozens of sites over the period. For a competitor, this is a near-real-time map of rivals’ buy-and-build; for a seller’s adviser, a shortlist of the most acquisitive counterparties. The technique generalises anywhere a regulator maintains a public site-and-operator register; the UK is simply where the record is most complete.

Exhibit 9 · The invisible market, by the numbers

UK regulated-care operator changes detected via same-address re-registration, 2011–2025.

Source: analysis of CQC published care-directory data (England), Open Government Licence. Excludes intra-group restructurings; categories inferred from registered site names.

Implications

9 · The origination map

Overlay the three axes on the main subsegments and a map emerges — not of where the demand is, but of where a platform can be built, where it would be a trap, and where the buyers already got there.

Exhibit 10 · Whitespace × legality × saturation, by subsegment

Where the three axes align (build), where the law blocks (trap / non-market), and where consolidation has already run (late).

Corryk Research synthesis of the ownership-law perimeter (Exhibit 3), public consolidation (Exhibit 4) and the asset-deal record (Exhibits 6–9).

The discipline the map imposes is to stop underwriting fragmentation and start underwriting the intersection. The attractive-looking, deeply fragmented, high-demand markets — German and French pharmacy above all — are the ones to leave alone until a statute moves. The buildable positions are narrower: the clinician subsegments that are open, still fragmented and not yet crowded (optical, physiotherapy, dental outside the most-worked markets), and any closed market approaching a liberalisation that would open it the way Italy’s did. And in every open market, the origination edge is to read the regulator’s re-registration feed, where the real deal flow is visible before it is announced.

10 · Catalysts & the bottom line

Ownership-law reform — in both directions. The single largest value event in this sector is a wall moving. Italy’s 2017 opening created a market overnight; a comparable liberalisation in Germany, France or Spain would do the same on a far larger base. The reverse also happens: Germany’s tightening of investor-owned dental MVZ is a wall going up. And competition and health authorities across Europe are increasingly attentive to private-capital roll-ups in care — attention that raises the odds of new gates, especially in pharmacy and dental.

Fragmentation is the first slide in every healthcare roll-up and the least informative. What decides whether a fragmented market is a platform is whether the law lets you own it and whether the buyers already have. Across Europe those two facts carve the opportunity down to a much narrower set than the demand story suggests: a handful of open, still-fragmented clinician subsegments; the occasional closed market on the verge of opening; and, everywhere the roll-up is live, a steady stream of asset deals the deal wires never see. The map that matters is not of demand. It is of walls — where they stand, where they are moving, and where, behind them, the whitespace is still there for the taking.

— Corryk

Comments, corrections or questions on this article: perspectives@corryk.com.